CN106620206B - 一种治疗动脉粥样硬化的中药 - Google Patents
一种治疗动脉粥样硬化的中药 Download PDFInfo
- Publication number
- CN106620206B CN106620206B CN201710100141.4A CN201710100141A CN106620206B CN 106620206 B CN106620206 B CN 106620206B CN 201710100141 A CN201710100141 A CN 201710100141A CN 106620206 B CN106620206 B CN 106620206B
- Authority
- CN
- China
- Prior art keywords
- decocted
- pseudo
- traditional chinese
- chinese medicine
- 30min
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 22
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 28
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 19
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 12
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 12
- 241000545744 Hirudinea Species 0.000 claims abstract description 12
- 241000270666 Testudines Species 0.000 claims abstract description 12
- 241000935235 Fritillaria meleagris Species 0.000 claims abstract description 11
- 241000239226 Scorpiones Species 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000009835 boiling Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract description 2
- 238000001647 drug administration Methods 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 235000003143 Panax notoginseng Nutrition 0.000 description 4
- 241000180649 Panax notoginseng Species 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000024121 nodulation Effects 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063648 Cerebral artery stenosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 241000605372 Fritillaria Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010027396 Mesenteric artery stenosis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 241001629494 Nephelium Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010048988 Renal artery occlusion Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038381 Renal atrophy Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 206010060753 Type IV hyperlipidaemia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009552 doppler ultrasonography Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- -1 elastic fibers Proteins 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000020887 hyperlipoproteinemia type 3 Diseases 0.000 description 1
- 208000000522 hyperlipoproteinemia type IV Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及治疗动脉粥样硬化的中药，可有效解决动脉粥样硬化的用药问题，其解决的技术方案是，该中药是由以下重量计的原料药物制成：鳖甲12‑18g、太子参12‑18g、浙贝母12‑18g、全瓜蒌12‑18g、水蛭4‑6g、全虫8‑12g、红花12‑18g和三七粉2‑4g，本发明原料丰富，组份科学，合理配伍，互相支持，诸药合用共奏益气养阴，活血化痰，软坚消积之功效，有效用于治疗动脉粥样硬化，疗效好，用药安全，是治疗动脉粥样硬化药物上的创新。
Description
技术领域
本发明涉及医药领域，特别是一种治疗动脉粥样硬化的中药。
背景技术
动脉粥样硬化是西方发达国家的主要死亡原因。随着中国人民生活水平提高和饮食习惯改变，该病也成为中国主要死亡原因。动脉粥样硬化始发儿童时期而持续进展，通常在中年或者中老年出现症状。由于动脉粥样硬化斑块表现为脂质和坏死组织的骤聚，因此往往认为动脉粥样硬化是退行性病变。现在认为，本病变是多因素共同作用的结果，首先是病变处于平滑肌细胞、巨噬细胞及T淋巴细胞的聚集；其次是包括胶原、弹性纤维及蛋白质多糖等结缔组织基质和平滑肌细胞的增生；第三是脂质，其中主要含胆固醇结晶及游离胆固醇和结缔组织。粥样硬化斑块中脂质及结缔组织的含量决定斑块的稳定性以及是否易导致急性缺血事件发生，临床上的常用药物，临床效果不佳，毒副作用较大，而手术治疗创伤大，且容易复发，因此，治疗动脉粥样硬化药物上的改进是目前亟需解决的问题。
发明内容
针对上述情况，为解决现有技术之缺陷，本发明之目的就是提供一种治疗动脉粥样硬化的中药，可有效解决动脉粥样硬化的用药问题。
本发明解决的技术方案是，该中药是由以下重量计的原料药物制成：鳖甲12-18g、太子参12-18g、浙贝母12-18g、全瓜蒌12-18g、水蛭4-6g、全虫8-12g、红花12-18g和三七粉2-4g，其中，将上述原料药物除三七外混合在一起，加水浸没，浸泡30-60min，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，滤渣再加水浸没，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，合并两次滤液，加入三七粉，混匀即成。
本发明原料丰富，组份科学，合理配伍，互相支持，诸药合用共奏益气养阴，活血化痰，软坚消积之功效，有效用于治疗动脉粥样硬化，疗效好，用药安全，是治疗动脉粥样硬化药物上的创新。
具体实施方式
以下结合实施例对本发明的具体实施方式作进一步详细说明。
实施例1
本发明在具体实施时，可由以下重量计的原料药物制成：鳖甲13g、太子参17g、浙贝母13g、全瓜蒌17g、水蛭4g、全虫11g、红花11g和三七粉4g，其中，将上述原料药物除三七外混合在一起，加水浸没，浸泡30-60min，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，滤渣再加水浸没，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，合并两次滤液，加入三七粉，混匀即成。
实施例2
本发明在具体实施时，还可由以下重量计的原料药物制成：鳖甲15g、太子参15g、浙贝母15g、全瓜蒌15g、水蛭5g、全虫10g、红花15g和三七粉3g，其中，将上述原料药物除三七外混合在一起，加水浸没，浸泡30-60min，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，滤渣再加水浸没，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，合并两次滤液，加入三七粉，混匀即成。
实施例3
本发明在具体实施时，还可由以下重量计的原料药物制成：鳖甲17g、太子参13g、浙贝母17g、全瓜蒌13g、水蛭6g、全虫9g、红花17g和三七粉2g，其中，将上述原料药物除三七外混合在一起，加水浸没，浸泡30-60min，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，滤渣再加水浸没，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，合并两次滤液，加入三七粉，混匀即成。
在本发明组分中：
鳖甲：滋阴潜阳，退热除蒸，软坚散结。用于肝肾阴虚证；癥瘕积聚；
太子参：补益脾肺，益气生津。治肺虚咳嗽，脾虚食少，心悸，怔忡，水肿，消渴，精神疲乏；
浙贝母：清热化痰，散结消痈。用于风热、痰热咳嗽；瘰疬，瘿瘤，乳痈疮毒，肺痈；
全瓜蒌：清热涤痰，宽胸散结，润燥滑肠。用于肺热咳嗽，痰浊黄稠，胸痹心痛，结胸痞满，乳痈，肺痈，肠痈肿痛，大便秘结；
水蛭：破血逐瘀，通经，用于蓄血，症瘕，积聚，妇女经闭，干血成痨，跌扑损伤，目亦痛，云翳；
全虫：息风止痉，攻毒散结，通络止痛作用。痉挛抽搐，疮疡肿毒痰核瘰疬，风湿顽痹，顽固性偏正头痛；
红花：活血通经、祛瘀止痛。用于痛经，经闭，产后血晕，瘀滞腹痛，胸痹心痛，血积，跌打瘀肿，关节疼痛，中风瘫痪；
三七粉：三七粉的成分和三七主根一样，富含三七皂苷、三七多糖、三七素、黄酮有效成分，具有止血、活血化瘀、消肿定痛、滋补强壮、抗疲劳、耐缺氧、抗衰老、降血脂、降血糖、提高机体免疫功能等作用。
本发明对于气阴两虚、痰瘀互结、脉积形成致动脉粥样硬化疾病立益气养阴、活血化痰、软坚消积为治疗大法，以经验方消积软斑方加减应用，组方由鳖甲、太子参、浙贝母、全瓜蒌、水蛭、全虫、红花、三七组成，其中鳖甲软坚散结消积是为君药；浙贝母、全瓜蒌化痰；水蛭、全虫、红花、三七活血，共为臣药以达活血化痰之功；太子参益气养阴,扶助人体正气，为佐使之药。全方如此配伍，共奏益气养阴，活血化痰，软坚消积之功。
通过临床对照研究，发现本发明临床疗效显著，为临床治疗动脉粥样硬化疾病提供有效的、切实可行的从多病因多病机治疗动脉粥样硬化疾病的手段。临床疗效显著，用药安全，并经临床实验得到了充分证明，有关临床实验资料如下：
1、临床资料
1.1一般资料选取自2015年1月至2017年1月门诊患者206例，随机分为治疗组与对照组各103例。两组患者在性别、年龄、病程、病情等一般资料经统计学分析无显著性差异(P>0.05)，具有可比性。
2、诊断标准
1、患者常有血胆固醇、甘油三酯增高，高密度脂蛋白减低，脂蛋白电泳图形异常，多数患者表现为第Ⅲ或第Ⅳ型高脂蛋白血症。
2、X线检查可见主动脉伸长、扩张和扭曲，有时可见钙质沉着。
3、动脉造影可显示四肢动脉、肾动脉与冠状动脉由于粥样硬化所造成的管腔狭窄、病变部位及范围。
4、多普勒超声波检查有助于判断四肢动脉、肾动脉血流通畅情况。
3、纳入标准：
1、无症状隐匿期:(对应于I～IV和Va型病变)粥样硬化斑块已形成，但尚无明显狭窄，因此无器官受累临床表现。脂质条纹多于5～10岁的儿童开始，粥样斑块始见于20岁。
2、缺血期:(对应于Vb、Vc及部分Va型病变)粥样硬化斑块导致血管狭窄、器官缺血，根据累及器官不同临床表现也不同:①脑动脉狭窄:记忆力减退、头晕、头痛、晕厥。长期缺血可引起脑萎缩，表现为痴呆及精神变态。②冠状动脉狭窄:心肌缺血表现为心绞痛。长期缺血可导致心肌纤维化，表现为心功能减退、心力衰竭。③肾动脉狭窄:可引起顽固性高血压。④肠系膜动脉狭窄:消化不良、肠道张力降低。⑤四肢动脉狭窄:下肢发凉、麻木、间歇性跛行，严重时可持续性疼痛、足背动脉搏动感减弱或消失。⑥其它器官血管狭窄:出现相应器官缺血症状。
3、坏死期:动脉堵塞或血管腔内血栓形成造成相应器官组织坏死产生的症状:
①脑血管闭塞:表现为脑梗死，出现头痛、眩晕、呕吐，意识丧失、肢体偏瘫、偏盲、失语等。
②冠状动脉闭塞:表现为急性心肌梗死。
③肾动脉闭塞:肾区疼痛、少尿、发热等。
④肠系膜动脉闭塞:剧烈腹痛、腹胀、发热，肠壁坏死时，可引起便血、麻痹性肠梗阻、休克等。
⑤四肢动脉闭塞:表现为肢体坏疽。
⑥其它器官血管闭塞:出现相应器官组织坏死症状。
4、纤维化期:长期缺血导致相应器官组织纤维化萎缩而产生的症状:
①脑萎缩:可引起痴呆，表现为精神病态、行动失常、智力和记忆力减退、性格完全变态等。②心脏纤维化:心脏扩大、心功能不全、心率失常等。
③肾萎缩:可发展为肾衰竭。
(不少患者不经坏死期而进入纤维化期，而已进入纤维化期的患者也可重新进入缺血期)
4、治疗方案
4.1对照组患者均予服用消胆胺，4g-5g/次，3次/日，同时服用潘生丁每次25-50mg，一日3次。
4.2治疗组在对照组基础上配合本发明中药汤剂，早晚各一次，温服，每次200-300ml，60天为一个疗程；
4.3疗效判定标准
显效：临床症状明显减轻、实验室检查明显改善；
好转：临床症状减轻、实验室检查稍有改善；
无效：临床症状体征及心电图没有改善。
5、统计学处理
5.1按上述治疗方案，口服本发明给出的中药组合物汤剂，通过对206例动脉粥样硬化疾病病人随机分组，并顺利完成治疗、观察及数据统计分析工作。治疗组103例，显效68例，有效25例，无效10例，总有效率90.2％；对照组103例，显效65例，有效23例，无效15例，总有效率为85.4％。治疗组与对照组比较，显效、有效及总有效率有显著统计学差异，且服用本发明中药无明显不良反应，用药安全，治疗结果见表1。
表1两组治疗结果比较例(％)
6、结论
本发明组份科学，原料丰富，合理配伍，互相支持，诸药合用共奏益气养阴，活血化痰，软坚消积之功效，适用于气阴两虚，痰瘀互结，脉积形成的动脉粥样硬化，疗效好，用药安全，有效率高达90％以上，是中药上的一大创新，具有实际的临床意义。
Claims (4)
1.一种治疗动脉粥样硬化的中药，其特征在于，该中药是由以下重量计的原料药物制成：鳖甲12-18g、太子参12-18g、浙贝母12-18g、全瓜蒌12-18g、水蛭4-6g、全虫8-12g、红花12-18g和三七粉2-4g，其中，将上述原料药物除三七外混合在一起，加水浸没，浸泡30-60min，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，滤渣再加水浸没，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，合并两次滤液，加入三七粉，混匀即成。
2.根据权利要求1所述的治疗动脉粥样硬化的中药，其特征在于，由以下重量计的原料药物制成：鳖甲13g、太子参17g、浙贝母13g、全瓜蒌17g、水蛭4g、全虫11g、红花11g和三七粉4g，其中，将上述原料药物除三七外混合在一起，加水浸没，浸泡30-60min，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，滤渣再加水浸没，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，合并两次滤液，加入三七粉，混匀即成。
3.根据权利要求1所述的治疗动脉粥样硬化的中药，其特征在于，由以下重量计的原料药物制成：鳖甲15g、太子参15g、浙贝母15g、全瓜蒌15g、水蛭5g、全虫10g、红花15g和三七粉3g，其中，将上述原料药物除三七外混合在一起，加水浸没，浸泡30-60min，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，滤渣再加水浸没，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，合并两次滤液，加入三七粉，混匀即成。
4.根据权利要求1所述的治疗动脉粥样硬化的中药，其特征在于，由以下重量计的原料药物制成：鳖甲17g、太子参13g、浙贝母17g、全瓜蒌13g、水蛭6g、全虫9g、红花17g和三七粉2g，其中，将上述原料药物除三七外混合在一起，加水浸没，浸泡30-60min，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，滤渣再加水浸没，武火煎煮至沸腾后，改用文火煎煮20-30min，过滤，得滤液，合并两次滤液，加入三七粉，混匀即成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710100141.4A CN106620206B (zh) | 2017-02-23 | 2017-02-23 | 一种治疗动脉粥样硬化的中药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710100141.4A CN106620206B (zh) | 2017-02-23 | 2017-02-23 | 一种治疗动脉粥样硬化的中药 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106620206A CN106620206A (zh) | 2017-05-10 |
| CN106620206B true CN106620206B (zh) | 2019-12-06 |
Family
ID=58844957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710100141.4A Expired - Fee Related CN106620206B (zh) | 2017-02-23 | 2017-02-23 | 一种治疗动脉粥样硬化的中药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620206B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (zh) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | 一种通心络药物组合物及应用 |
| CN104042912A (zh) * | 2014-07-10 | 2014-09-17 | 崇州市地龙海龙生物制品开发研究所 | 一种医治冠状动脉粥样硬化性心脏病制剂的制备方法 |
| CN104873633A (zh) * | 2015-06-11 | 2015-09-02 | 公安县中医医院 | 一种治疗心脑血管疾病的中药药丸 |
-
2017
- 2017-02-23 CN CN201710100141.4A patent/CN106620206B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (zh) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | 一种通心络药物组合物及应用 |
| CN104042912A (zh) * | 2014-07-10 | 2014-09-17 | 崇州市地龙海龙生物制品开发研究所 | 一种医治冠状动脉粥样硬化性心脏病制剂的制备方法 |
| CN104873633A (zh) * | 2015-06-11 | 2015-09-02 | 公安县中医医院 | 一种治疗心脑血管疾病的中药药丸 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106620206A (zh) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101396543B (zh) | 治疗心血管系统疾病的纯中药制剂 | |
| CN101168021B (zh) | 治疗心脑疾病的药物 | |
| CN110934294A (zh) | 具有减肥美容功效的组合物及其制备方法 | |
| CN103182012A (zh) | 一种治疗缺血性脑中风的药物及其制备方法 | |
| CN106620206B (zh) | 一种治疗动脉粥样硬化的中药 | |
| CN103393943A (zh) | 一种治疗脑梗塞后遗症的中药组合物 | |
| CN104338052A (zh) | 治疗脑血栓的中药配方 | |
| CN102626471B (zh) | 一种具有防敏脱敏、修复再生作用的中药组合物 | |
| CN102552715B (zh) | 中药组合物、含有该组合物的药物及其制备方法 | |
| CN110464803A (zh) | 一种用于降低血压的中药组合物及其制备方法 | |
| CN102755444A (zh) | 一种用于治疗高血脂症的中药组合物及其制备方法 | |
| CN114767816B (zh) | 一种治疗冠心病的中药组合物及其制备方法 | |
| CN107485698A (zh) | 一种具有养血通络、美容养颜功效的中药组合物及其制备方法 | |
| CN102614459B (zh) | 快速治疗心肌缺血的中药喷雾剂及其制备方法 | |
| CN102526343B (zh) | 补气活血通络中药组合物 | |
| CN113456794A (zh) | 一种通梗化瘀药物组合物及其制备方法 | |
| CN104784444A (zh) | 一种治疗高血压性心脏病的中药组合物及其制备方法 | |
| CN105434903A (zh) | 一种治疗冠心病的中药制剂 | |
| CN112972581A (zh) | 一种参凤静心组合物及其制备方法 | |
| CN106309926A (zh) | 蜂产品及药食两用食物治疗胃炎胃溃疡的组合物 | |
| CN103933368B (zh) | 用于治疗产后便秘的药物组合物及其制备方法 | |
| CN112806572A (zh) | 一种治疗冠心病的五谷杂粮粉 | |
| CN111686174A (zh) | 一种中药配方及其应用 | |
| CN104288377A (zh) | 一种治疗脑血栓的药物组合物 | |
| CN105709071A (zh) | 用于治疗产后便秘的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |